Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT

Clinical trial NCT05914675 · UNKNOWN

Trial details

NCT number: NCT05914675
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation

Start date: 2023-07-01
Primary completion: 2024-12-31
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.